Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1101

Inhibition of dengue infection by binding of drugs to a novel site on dengue E protein.

Inventors: Stephen Harrison, Yorgo Modis

Invention Types: Therapeutics

Research Areas: Infectious Disease

Keywords: Drug Discovery, Drug Screening, Drug Design

For More Information Contact:  Caron, Connie

 

Invention Description:

This invention identifies novel druggable regions in viral class II E proteins; the modulation of activity of such regions could inhibit fusion and, hence, infectivity. The invention also provides methods of screening compounds against the druggable regions in order to discover candidate therapeutics. A better understanding of the structure and activity of class II envelope fusion proteins and potentially druggable regions within will further the development of anti-viral fusion inhibitors for flaviviruses, alphaviruses, and hepatitis viruses.

Applications:

Inhibition of viral fusion by small molecule drugs is a promising treatment or prophylactic, as has been demonstrated by anti-HIV fusion inhibitors. Success in inhibition of Dengue virus fusion could lead to similar success against other related flaviviruses infections (such as yellow fever and West Nile), alphaviruses (such as Sindbis and Semliki Forest viruses), as well as Hepatitis C. Present invention could be used in Drug Designing, Drug Discovery and Drug Screening.

Competitive Advantages:

Currently, there is no known cure or vaccine for Dengue fever and infection rates are rapidly increasing. There is no specific treatment for infection, and control of dengue virus by vaccination has proven elusive.

Business Opportunity:

Dengue fever affects about 50 million people across five continents, and is spreading into the southern United States. Estimates suggest that over one-half million victims, many of whom are children, require hospitalization annually. Boston Children's hospital is looking to Exclusive/Non-Exclusive license this technology for development.

Key Publications: PNAS 2003 Vol. 100: 6986-91;|
Nature 2004 Vol. 427: 313-19;

J. Virol. 2005 Vol. 79: 12233-31.

IPStatus: Patented